根据消息,Viking Therapeutics公司(股票代码:VKTX)在盘前交易中股价大涨10.61%,引发市场关注。
造成VKTX股价大涨的主要原因是,它的竞争对手安健公司近期公布了一项实验性减肥药MariTide的临床试验结果。该试验结果显示,经过治疗,患者平均体重只减轻了20%,远低于投资者的预期。
与此同时,VKTX和礼来公司正在研发的其他减肥药物则取得了不错的临床表现。礼来的注射减肥药Zepbound在一项为期72周的试验中,帮助患者平均减重超过22%。VKTX的候选药物VK2735在今年早些时候的一项中期研究中,也帮助患者平均减轻近15%的体重。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.